Review papers with raw data transparency

Concise critical takeaway

The systematic review identifies 84 studies implicating 27 TRIM proteins in kidney cancer, 14 in bladder cancer, 28 in prostate cancer and 1 in testicular cancer, and highlights recurrent pathways (TGFbeta, PI3KAKTmTOR, EMT) and mixed tumorpromoting versus tumorsuppressive roles across TRIM family members — a valuable map of existing literature but limited by heterogeneity, variable functional validation, and lack of meta-analysisCancers 2025 systematic review on TRIM proteins in urological cancers

Full critical review and appraisal

What the paper did well

• Comprehensive literature capture to 31 May 2024, registered in PROSPERO and using PRISMA methods, which increases methodological transparency for a qualitative synthesisMethods and registration details
• Clear, useful summary tables mapping individual TRIM proteins to cancer type, reported directionality (oncogenic vs tumor suppressive), and implicated pathways (for example TRIM24 TRIM37 TRIM44 TRIM59 among promoters; TRIM2 TRIM7 TRIM8 TRIM21 among suppressors) which serves as a reference for researchers and cliniciansSummary tables of TRIM roles

Major limitations and caveats

1. Heterogeneity of primary evidence The review pools mechanistic cell line studies bioinformatics analyses IHC and limited in vivo work without formal stratification or meta analytic weighting; therefore apparent patterns (eg TRIM24 oncogenic) may reflect publication bias or overrepresentation of certain experimental systems rather than consistent biology across patient cohortsHeterogeneity and limitations statement
2. Binary labeling hides context dependence The classification of TRIMs as tumor promoting or suppressive is frequently context dependent (tumor subtype cell line genetic background tumor microenvironment). For example TRIM19/PML shows both tumor suppressive and tumor promoting reports in different studies; binary labels risk overgeneralizationMixed roles of TRIM19 and TRIM33
3. Uneven experimental rigor Many TRIM assignments are based on single papers or bioinformatic correlations (eg TCGA expression associations) without orthogonal functional validation; the review does not formally grade evidence strength per TRIM (eg GRADE) which would help prioritize targets for follow up studiesLack of evidence grading
4. Temporal cutoff and omission risk Search ended May 31 2024 so subsequent 2024–2025 studies may alter classifications; the review acknowledges this time window and supplies supplementary materials but readers must confirm the state of evidence when planning experiments or translational workSearch cutoff and need for future studies
5. Clinical translation jump The review suggests TRIMs as potential therapeutic targets but stops short of evaluating druggability specificity off target effects or existing small molecule or biologic approaches against TRIM E3 ligases or interacting pathways; that leap requires careful target validation and chemical biology which is not present hereTranslational claim caution

Detailed evidence highlights and contradictions

• Kidney cancer: 27 TRIMs reported; 9 labeled oncogenic (eg TRIM24 TRIM27 TRIM37 TRIM44 TRIM46 TRIM47 TRIM59 TRIM63 TRIM65) and 9 tumor suppressors (eg TRIM2 TRIM7 TRIM8 TRIM13 TRIM21 TRIM26 TRIM28 TRIM33 TRIM58). Several functional studies show TRIM47 promotes RCC by p53 degradation and TRIM44 by regulating FRK; TRIM33 and TRIM28 show conflicting roles in different datasets/models suggesting context dependenceKidney cancer TRIM evidence
• Bladder cancer: 14 TRIMs implicated with TRIM9 TRIM25 TRIM26 TRIM28 TRIM29 TRIM59 TRIM65 TRIM66 commonly labeled oncogenic and TRIM19 TRIM38 as suppressive; mechanisms include CEACAM6SMAD2/3 NFkappaB and AKT signalling links and functional studies report effects on proliferation invasion and chemosensitivity but many studies are cell line basedBladder cancer TRIM evidence
• Prostate cancer: broad evidence set with TRIM24 TRIM28 TRIM59 among oncogenic drivers in CRPC contexts and TRIM36 TRIM32 as tumor suppressors; mechanistic links to AR signalling TRIM28TRIM24 interactions SPOPmediated degradation and m6Arna reader YTHDF1 regulation of TRIM68 are noted demonstrating multilayered regulation at transcriptional posttranscriptional and posttranslational levels but again clinical validation is sparseProstate cancer TRIM evidence and mechanism

Practical recommendations for researchers

1. Prioritise TRIMs for followup using objective criteria: reproducible patient level associations (TCGA/CPTAC), orthogonal functional validation (knockout and rescue in multiple models), in vivo efficacy and evidence of mechanism (substrate identification) rather than single study effectsRecommendation for prioritisation and validation
2. Use standardized evidence grading (eg adapted GRADE for mechanistic studies) and report effect sizes not only directionality; perform meta analyses where homogeneous quantitative data exist.
3. Map TRIM domain architecture and E3 ligase dependency when proposing therapeutic strategies because many TRIMs lack canonical RING domains and may act via alternative mechanisms (deubiquitination scaffold or Bbox mediated activity) — this affects druggability and selection of degrader modalities or inhibitorsTRIM structural diversity and functional implications

What would change the main conclusions

If large well controlled patient cohort analyses and multiple orthogonal in vivo loss and gain of function studies failed to reproduce the associations reported for leading TRIM candidates (eg TRIM24 TRIM44 TRIM59) or showed opposite directionality the current mapping would be falsified — the review correctly frames itself as a snapshot and a hypothesisgenerator rather than definitive proof of clinical utilityAuthors note on falsifiability

Quick prioritized action list

1. Replicate top TRIM hits across independent RCC bladder and prostate patient cohorts linking expression to survival and molecular subtype (eg TRIM24 TRIM44 TRIM59 TRIM28 TRIM36)
2. Perform CRISPR knockout and rescue with catalytically dead mutants in multiple cell lines and orthotopic in vivo models to establish causality
3. Identify direct ubiquitination substrates via unbiased ubiquitin remnant profiling and validate with biochemical assays to reveal druggable nodes
4. Assess druggability: screen for small molecule inhibitors E3 ligase modulators or develop PROTAC based strategies using structural information on TRIM domains

Confidence and concluding judgement

Overall the review is a rigorous and useful synthesis that compiles disparate TRIM literature into a navigable resource for urological cancer researchers however its conclusions are appropriately provisional: the evidence is heterogeneous and often preliminary so translational claims require additional highquality validation and formal evidence gradingOverall conclusions and caution